Team Drea Foundation is launching a customizable wellness challenge that seeks to raise $50,000 in 50 days for amyotrophic lateral sclerosis (ALS) research. The 50for50 challenge invites people to set a personal goal related to the number 50, such as 50 pushups a day or 50 acts…
News
Minnesota lawmakers have passed legislation that will provide $25 million for amyotrophic lateral sclerosis (ALS) research and to support ALS caregivers in the state. Under the law (SF 3372), the Minnesota Office of Higher Education will receive $20 million to award research grants to scientists studying all areas of…
A CRISPR-based gene editing system could be used to reduce the activity of genes associated with amyotrophic lateral sclerosis (ALS) and Huntington’s disease, a new study shows. The study, “Targeted gene silencing in the nervous system with CRISPR-Cas13,” was published in Science Advances. CRISPR is a strategy that…
Treatment with Radicava (edaravone) for at least one year significantly reduces the risk of death in people with amyotrophic lateral sclerosis (ALS), prolonging their survival for about six months compared with those not given the therapy, an analysis of U.S. real-life data shows. “Real-world data may provide additional insight…
Synchron’s Stentrode, an innovative, implantable brain computer interface (BCI), was found safe in four amyotrophic lateral sclerosis (ALS) patients and let them communicate and perform daily online tasks by using “just their thought,” according to one-year data from a clinical trial. The results were presented as part of…
There is no substantial evidence supporting the efficacy of Amylyx Pharmaceuticals’ AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), according to a 6–4 vote by a U.S. Food and Drug Administration (FDA) advisory committee. The close vote against the therapy came at the end of a virtual…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to InFlectis BioScience’s experimental therapy IFB-088 for amyotrophic lateral sclerosis (ALS). Orphan drug status is given to treatment candidates with the potential to be safe and effective in rare diseases. In the U.S. rare diseases are defined as…
Regulus Therapeutics, in partnership with researchers at Brigham and Women’s Hospital, has initiated studies to evaluate a library of molecules designed to suppress microRNA-155 (miR-155) — a small molecule that regulates the activity of other genes — as a potential treatment for amyotrophic lateral sclerosis (ALS). The agreement, effective…
Cells contain certain chaperone proteins that can break down the protein clumps found in amyotrophic lateral sclerosis (ALS) and Huntington’s disease, but don’t always activate the right proteins at the right time, a recent study shows. “[The cells] do not always realize there is a problem, or know…
A new rapid test is under development that will be able to detect seafood and water levels of an environmental toxin called beta-N-methylamino-L-alanine (BMAA), the exposure to which has been implicated as a risk factor for amyotrophic lateral sclerosis (ALS). The efforts will be spearheaded by Brain Chemistry…
Recent Posts
- A story of a family’s loss offers guidance amid my grief with ALS
- MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS
- Holding the line: Why I’d keep my ALS progression exactly as it is
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- MDA 2026: New ALS platform trial adds RT1999 to speed search for treatments